Evaluation of Arsenic Trioxide-Loaded Albumin Nanoparticles as Carriers: Preparation and Antitumor Efficacy

REFERENCES

• Ambruosi A., Khalansky A. S., Yamamoto H., Gelperina S. E., Begley D. J., Kreuter J. Biodistribution of polysorbate 80-coated doxorubicinloaded[14c]- poly (butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J. Drug Target 2006; 14: 97–105
   PubMed Web of Science ®Google Scholar
• Arnedo A., Espuelas S., Irache J. M. Albumin nanoparticles as carriers for a phosphodiester oligonucleotide. Int. J. Pharm. 2002; 244: 59–72
   PubMed Web of Science ®Google Scholar
• Arnedo A., Irache J. M., Merodio M., Espuelas Millán M. S. Albumin nanoparticles improved the stability, nuclear accumulation and anticytomegaloviral activity of a phosphodiester oligonucleotide. J. Control. Release 2004; 94: 217–227
   PubMed Web of Science ®Google Scholar
• Barraud L., Merle P., Soma E., Lefrancois L., Guerret S., Chevallier M., Dubernet C., Couvreur P., Trepo C., Vitvitski L. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J. Hepatol. 2005; 42: 736–743
   PubMed Web of Science ®Google Scholar
• Bernardini S., Nuccetelli M., Noguera N. I., Bellincampi L., Lunghi P., Bonati A., Mann K., Miller W. H., Federici G., Lo Coco F. Role of GSTP1-1 in mediating the effect of As2O3 in the acute promyelocytic leukemia cell line NB4. Ann. Hematol. 2006; 85: 681–687
   PubMed Web of Science ®Google Scholar
• Diaz Z., Laurenzana A., Mann K. K., Bismar T. A., Schipper H. M., Miller W. H. Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity. Leukemia 2007; 21: 2117–2127
   PubMed Web of Science ®Google Scholar
• Dreis S., Rothweiler F., Michaelis M., Cinatl J., Jr., Kreuter J., Langer K. Preparation, characterization and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int. J. Pharm. 2007; 341: 207–214
   PubMed Web of Science ®Google Scholar
• Eatock M., Church N., Harris R., Angerson W., McArdle C., French R., Twelves C. Activity of doxorubicin covalently bound to a novel human serum albumin microcapsule. Invest. New Drugs 1999; 17: 111–120
   PubMed Web of Science ®Google Scholar
• Evens A. M., Tallman M. S., Gartenhaus R. B. The potential of arsenic trioxide in the treatment of malignant disease: Past, present, and future. Leuk. Res. 2004; 28: 891–900
   PubMed Web of Science ®Google Scholar
• Illum L., Davis R. M., Wilson C. G. Blood clearance and organ deposition of intravenously administered colloidal particles. The effects of particle size, nature and shape. Int. J. Pharm. 1982; 2: 135–146
   Google Scholar
• Irache J. M., Merodio M., Arnedo A., Camapanero M. A., Mirshahi M., Espuelas S. Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs. Mini. Rev. Med. Chem 2005; 5: 293–305
   PubMed Web of Science ®Google Scholar
• Jiang X. H., Wong B. C., Yuen S. T., Jiang S. H., Cho C. H., Lai K. C., Lin M. C., Kung H. F., Lam S. K. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int. J. Cancer 2001; 91: 173–179
   PubMed Web of Science ®Google Scholar
• Labib A., Lenaerts V., Chouinard F., Leroux J. C., Ouellet R., van Lier J. E. Biodegradable nanospheres containing phthalocyanines and naphthalocyanines for targeted photodynamic tumor therapy. Pharm. Res. 1991; 8: 1027–1031
   PubMed Web of Science ®Google Scholar
• Lemarie A., Morzadec C., Bourdonnay E., Fardel O., Vernhet L. Human macrophages constitute targets for immunotoxic inorganic arsenic. J. Immunol. 2006; 177: 3019–3027
   PubMed Web of Science ®Google Scholar
• Li F. Q., Su H., Wang J., Liu J. Y., Zhu Q. G., Fei Y. B., Pan Y. H., Hu J. H. Preparation and characterization of sodium ferulate entrapped bovineserum albumin nanoparticles for liver targeting. Int. J. Pharm. 2007; 11: 274–282
   Google Scholar
• Lin W., Coombes A. G., Davies M. C., Davis S. S., Illum L. Preparation of Sub-100 nm human serum albumin nanospheres using a ph-coacervation method. J. Drug Targeting. 1993; 1: 237–243
   PubMed Web of Science ®Google Scholar
• Liu P., Han Z. C. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: Review of clinical and basic studies. Int. J. Hematol. 2003; 78: 32–39
   PubMed Web of Science ®Google Scholar
• Liu B., Pan S., Dong X., Qiao H., Jiang H., Krissansen G. W., Sun X. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci. 2006; 97: 675–681
   PubMed Web of Science ®Google Scholar
• Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J. Control. Release 2000; 65: 271–284
   PubMed Web of Science ®Google Scholar
• Mathews V., George B., Lakshmi K. M., Viswabandya A., Bajel A., Balasubramanian P., Shaji R. V., Srivastava V. M., Srivastava A., Chandy M. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity. Blood 2006; 107: 2627–2632
   PubMed Web of Science ®Google Scholar
• Moghimi S. M., Hedeman H., Muir I. S., Illum L., Davis S. S. An investigation of the filtration capacity and the fate of large filtered sterically-stabilized microspheres in rat spleen. Biochim. Biophys. Acta 1993; 3: 233–240
   Google Scholar
• Moghimi S. M., Porter C. J., Muir I. S., Illum L., Davis S. S. Non-phagocytic uptake of intravenously injected microspheres in rat spleen: Influence of particle size and hydrophilic coating. Biochem. Biophys. Res. Commun. 1999; 127: 861–866
   Google Scholar
• Park J. W., Choi Y. J., Jang M. A., Baek S. H., Lim J. H., Passaniti T., Kwon T. K. Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells. Biochem. Biophys. Res. Commun. 2001; 286: 726–734
   PubMed Web of Science ®Google Scholar
• Porter C. J., Moghimi S. M., Illum L., Davis S. S. The polyoxyethylene/polyoxy-propylene block co-polymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. FEBS Lett. 1992; 305: 62–66
   PubMed Web of Science ®Google Scholar
• Rubenstein J. L., Kim J., Ozawa T., Zhang M., Westphal M., Deen D. F., Shuman M. A. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000; 2: 306–314
   PubMed Web of Science ®Google Scholar
• Sahu G. R., Jena R. K. Significance of intracellular arsenic trioxide for therapeutic response in acute promyelocytic leukemia. Am. J. Hematol. 2005; 78: 113–116
   PubMed Web of Science ®Google Scholar
• Santhi K., Dhanaraj S. A., Joseph V., Ponnusankar S., Suresh B. A. Study on the preparation and anti-tumor efficacy of bovine serum albumin nanospheres containing 5-fluorouracil. Drug Dev. Ind. Pharm. 2002; 28: 1171–1179
   PubMed Web of Science ®Google Scholar
• Santhi K., Dhanaraj S. A., Koshy M., Ponnusankar S., Suresh B. Study of bio- distribution of methotrexate-loaded bovine serum albumin nanospheres in mice. Drug Dev. Ind. Pharm. 2000; 26: 1293–1296
   PubMed Web of Science ®Google Scholar
• Siu C. W., Au W. Y., Yung C., Kumana C. R., Lau C. P., Kwong Y. L., Tse H. F. Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: Implications for long-term cardiac safety. Blood 2006; 108: 103–106
   PubMed Web of Science ®Google Scholar
• Steiniger S. C., Kreuter J., Khalansky A. S., Skidan I. N., Bobruskin A. I., Smirnova Z. S., Severin S. E., Uhl R., Kock M., Geiger K. D., Gelperina S. E. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int. J. Cancer 2004; 109: 759–767
   PubMed Web of Science ®Google Scholar
• Verstovsek S., Giles F., Quintás-Cardama A., Perez N., Ravandi-Kashani F., Beran M., Freireich E., Kantarjian H. Arsenic derivatives in hematologic malignancies: A role beyond acute promyelocytic leukemia. Hematol. Oncol. 2006; 24: 181–188
   PubMed Web of Science ®Google Scholar
• Yoo H. S., Oh J. E., Lee K. H., Park T. G. Biodegradable nanoparticles containing doxorubicin–PLGA conjugate for sustained release. Pharm. Res. 1999; 16: 1114–1118
   PubMed Web of Science ®Google Scholar
• Zhang L., Hou S., Mao S., Wei D., Song X., Lu Y. Uptake of folate-conjugated albumin nanoparticles to the SKOV3 cells. Int. J. Pharm. 2004; 287: 155–162
   PubMed Web of Science ®Google Scholar
• Zhou J., Zeng F. Q., Li C., Tong Q. S., Gao X., Xie S. S., Yu L. Z. Preparation of arsenic trioxide-loaded albuminutes immuno-nanospheres and its specific killing effect on bladder cancer cell in vitro. Chin. Med. J (Engl). 2005; 118: 50–55
   PubMed Web of Science ®Google Scholar
• Zhu Q., Zhang J. W., Zhu H. Q., Shen Y. L., Flexor M., Jia P. M., Yu Y., Cai X., Waxman S., Lanotte M., Chen S. J., Chen Z., Tong J. H. Synergic effects of arsenictrioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood 2002; 99: 1014–1022
   PubMed Web of Science ®Google Scholar